Investor Presentaiton

Income statement DKKm Revenue Gross profit SG&A costs Q2 2021/22 Q2 2022/23 Change H1 2021/22 H1 2022/23 Change 5,502 6,061 10% 10,671 12,166 14% 3,781 4,027 7% 7,311 8,173 12% -1,884 -2,159 15% -3,571 -4,321 21% R&D costs -222 -209 -6% -427 -425 0% Other operating income/expenses 11 12 9% 22 18 -18% Operating profit (EBIT) before special items 1,686 1,671 -1% 3,335 3,445 3% Special items -381 -20 nm -415 -33 nm Operating profit (EBIT) 1,305 1,651 27% 2,920 3,412 17% Net financial items -18 -190 nm -76 -524 nm Ταχ Net profit Key ratios -307 -306 0% -657 -606 -8% 980 1,155 18% 2,187 2,282 4% Gross margin 69% 66% 69% 67% EBIT margin before special items 31% 28% 31% 28% EBIT margin 24% 27% 27% 28% Earnings per share (EPS) before special items, diluted 5.99 5.51 -8% 11.77 10.86 -8% 92 22 Coloplast

View entire presentation